New Hope in Breast Cancer Treatment: Giredestrant's Promising Results

Roche's experimental drug giredestrant reduced the risk of breast cancer recurrence by 30% compared to standard treatments. Phase III trial results suggest it could become a new standard in endocrine therapy, addressing unmet needs in ER-positive breast cancer. Safety profile is favorable, with fewer discontinuations due to side effects.

Roche announced its experimental drug giredestrant has significantly reduced breast cancer recurrence by 30% compared to standard endocrine therapies. This breakthrough is hailed as a major advancement in hormonal treatment for the disease, marking the first significant progress in over two decades.

The phase III trial, known as lidERA, highlighted that, after three years, 92.4% of patients treated with giredestrant were both alive and disease-free, in contrast to 89.6% of those receiving standard care. Chief Medical Officer Levi Garraway noted the drug's impact on improving disease-free survival rates during an interview.

Giredestrant's promising results specifically target ER-positive breast cancer, which represents a majority of cases. While the results are promising, ongoing discussions focus on which patients may require additional treatment with CDK4/6 inhibitors like Novartis' Kisqali. The drug's favorable safety profile could drive significant business, with projections of $5 billion in yearly revenue if approved.

(With inputs from agencies.)